Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Maria Fardis - Chief Executive Officer & President Friedrich Finckenstein - Chief Medical Officer Jean Marc Bellemin - Chief Financial Officer Sara Pellegrino - Vice President, Investor and Public Relations Jim Ziegler - Senior Vice President, Commercial Conference Call Participants Michael Yee - Jefferies LLC Peter Lawson - Barclays Bank Mark Breidenbach - Oppenheimer Boris Peaker - Cowe ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | --- | --- ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | --- | --- ...

| --- | --- | --- | --- | --- | |---------------------------------------------------------------------------|--------------------------------------|-------|---------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors | | | February 2021 | | | | © 2021, Iovance Biotherapeutics, Inc | | | 1 | | --- ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Maria Fardis - Chief Executive Officer & President Friedrich Finckenstein - Chief Medical Officer Jean Marc Bellemin - Chief Financial Officer Sara Pellegrino - Vice President, Investor and Public Relations Conference Call Participants Mark Breidenbach - Oppenheimer Peter Lawson - Barclays Bank Biren Amin - Jefferies Reni Benjamin - JMP Securities Mara Goldstein - Mizuho Securities ...

| --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|---------------------------------|-------|---------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer | | | November 2020 | | | | © 2020, Iovance Biotherapeutics | | | | ongoing clinical trials and anticipated clinical trials for our current product candidates (including both Company ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Sara Pellegrino - VP, IR & Public Relations Maria Fardis - CEO, President & Director Friedrich Finckenstein - Chief Medical Officer Michael Swartzburg - VP, Finance and Interim Principal Financial Officer & Principal Accounting Officer Conference Call Participants Peter Lawson - Barclays Bank Mara Goldstein - Mizuho Securities Mark Breidenbach - Oppenheimer Boris Peaker - Cowen and C ...

Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer October 2020 Forward Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this presentation, filings with the Securities and Exchange Commission ("SEC") ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Sara Pellegrino - Vice President Investor and Public Relations Maria Fardis - President and Chief Executive Officer Friedrich Finckenstein - Chief Medical Officer Michael Swartzburg - Vice President of Finance and Principal Accounting Officer Jim Ziegler - Head of Commercial Conference Call Participants Peter Lawson - Barclays Jim Birchenough - Wells Fargo Ben Burnett - Stifel Mara Gol ...

| --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. U.S. and Europe), such as statements regarding the timing of initiation and completion of these trials; the timing of and our ability to successfully submit, obtain and maintain FDA or designation ("BTD" ...